lapatinib / Generic mfg. 
Welcome,         Profile    Billing    Logout  

58 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lapatinib / Generic mfg.
2010-022737-28: A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ERb B2 positive metastatic breast cancer developing braiN metastasis /es

Ongoing
4
130
Europe
TYKERB (Lapatinib), Herceptin (Trastuzumab), Xeloda (Capecitabine), GEW00474, RO 45-2317, TYKERB, Herceptin, Xeloda, TYKERB, Herceptin, Xeloda
Leeds Teaching Hospitals NHS Trust
Patients with ERB B2 positive metastatic breast cancer developing brain metastasis/es
 
 
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
ChiCTR-OPC-17011664: A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refractory Cushing's disease

Not yet recruiting
4
30
 
lapatinib
Peking Union Medical College Hospital; Peking Union Medical College Hospital, 12th Five-Year technology support program
Pituitary ACTH-secreting adenoma
 
 
ChiCTR1800018500: One-arm, single-center, open-label clinical study of lapatinib mesylate combined with docetaxel in the treatment of lung adenocarcinoma with no driver gene mutation

Not yet recruiting
4
20
 
Apatinib combined with docetaxel
The People's Hospital of Tongliang District, Chongqing; The People's Hospital of Tongliang District.Chongqing City, Jiangsu hengrui pharmaceutical co. LTD
Lung adenocarcinoma without driver gene mutation
 
 
LOGiC, NCT00680901 / 2007-005725-29: - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Checkmark ESMO 2013
Sep 2013 - Sep 2013: ESMO 2013
Checkmark For advanced HER2-positive gastric cancer
Jun 2013 - Jun 2013: For advanced HER2-positive gastric cancer
Checkmark ASCO-2013
More
Active, not recruiting
3
545
Europe, Canada, US, RoW
Lapatinib, Tykerb, Tyverb, Placebo, Capecitabine, Oxaliplatin
Novartis Pharmaceuticals
Neoplasms, Gastrointestinal Tract
09/12
10/24
CALGB-40601, NCT00770809: Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark ASCO 2013
More
Active, not recruiting
3
305
US
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tykerb, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Trastuzumab, ABP 980, ALT02, Biceltis, CANMab, CT-P06, CT-P6, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Hercessi, Herclon, Hertraz, Herwenda, Herzuma, Kanjinti, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, Trastuzumab Biosimilar CT-P6, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-herw, Trastuzumab-pkrb, Trastuzumab-qyyp, Trastuzumab-strf, Trastuzumab-zerc, Trazimera, Zercepac
National Cancer Institute (NCI)
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
01/14
07/25
CTRIAL-IE (ICORG) 11-10, NCT01526369: A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Completed
3
75
Europe, RoW
Trastuzumab, Paclitaxel, Lapatinib
Cancer Trials Ireland
Metastatic Breast Cancer
11/15
02/23
EPHOS-B, NCT01104571 / 2008-005466-30: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

Checkmark P3 trial design
Dec 2011 - Dec 2011: P3 trial design
Active, not recruiting
3
257
Europe
trastuzumab, lapatinib ditosylate, laboratory biomarker analysis, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Institute of Cancer Research, United Kingdom, University of Manchester, Manchester University NHS Foundation Trust, Cancer Research UK, Novartis
Breast Cancer
08/17
09/25
BO29919, NCT03084939: Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Completed
3
351
RoW
Trastuzumab Emtansine, Kadcyla, Lapatinib, Capecitabine
Hoffmann-La Roche
Breast Cancer
11/18
03/23
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
TULIP, NCT03262935 / 2017-001994-18: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Completed
3
437
Europe, Canada, US, RoW
(vic-)trastuzumab duocarmazine, SYD985, Trastuzumab vc-seco-DUBA, Physician's choice, Lapatinib (Lap), Capecitabine (Cap), Trastuzumab (T), Vinorelbine (Vino), Eribulin (Eri)
Byondis B.V.
Metastatic Breast Cancer
03/21
06/22
ChiCTR1900027887: A clinical study for evaluating the efficacy and safety of BAT8001 injection for the treatment of HER2-positive advanced breast cancer

Recruiting
3
410
 
3.6 mg/kg, q3w, administered intravenously ;Lapatinib dose: Qd, 1250 mg/dose, administered on days 1-21 of each cycle; Capecitabine dose: Bid, 1000 mg/m2, administered on days 1-14 of each cycle, rest on days 15-21.
Sun Yat-sen University Cancer Center; Bio-thera Solutions, Ltd., Self-raised funds
HER-2 positive advanced breast cancer
 
 
NCT06313983: A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Recruiting
3
339
RoW
Hemay022+AI, Lapatinib+Capecitabine
Tianjin Hemay Pharmaceutical Co., Ltd
Breast Cancer
12/25
06/26
DESTINY-Breast02, NCT03523585 / 2018-000221-31: DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread []

Hourglass Jan 2024 - Jun 2024 : Approval in EU for 3L HER2+ breast cancer (based on DESTINY-Breast02 trial)
Hourglass Jan 2022 - Dec 2022 : Acceptance of regulatory submission in US for pre-treated HER2 breast cancer (based on DESTINY-Breast02 trial)
Checkmark Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Data from DESTINY-Breast02 trial for HER2-positive, unresectable and/or metastatic breast cancer at SABCS 2022
Checkmark Presentation of primary data from DESTINY-Breast02 trial for HER2 +ve breast cancer
More
Active, not recruiting
3
608
Europe, Japan, US, RoW
Trastuzumab deruxtecan, DS-8201a, T-DXd, Capecitabine, Investigator's Choice Comparative Therapy, Lapatinib, Trastuzumab
Daiichi Sankyo, Daiichi Sankyo Co., Ltd., AstraZeneca
Breast Cancer
06/22
05/25
CTR20200806: Phase III study of TAA013 versus lapatinib combined with capecitabine in patients with HER2-positive breast cancer

Terminated
3
438
China
TAA013 - TOT Biopharm
Dong Yao Pharmaceutical Co., Ltd.
Locally advanced or metastatic HER2-positive breast cancer
 
 
MULTISARC, NCT03784014: Molecular Profiling of Advanced Soft-tissue Sarcomas

Active, not recruiting
3
603
Europe
Nilotinib, TASIGNA, Ceritinib, ZYKADIA, Capmatinib, Lapatinib, TYVERB, Trametinib, MEKINIST, Trametinib and Dabrafenib, MEKINIST and TAFINLAR, Olaparib and Durvalumab, LYNPARZA, MEDI4736, Palbociclib, IBRANCE, PD-0332991, Glasdegib, PF-04449913, TAS-120, Next Generation sequencing exome, RNA Seq, NGS, High throughput sequencing
Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Institut Bergonié, Plateforme labellisée Inca - Institut Bergonié, Bordeaux, Plateforme labellisée Inca - Hôpital Européen Georges Pompidou, Paris, EUCLID Clinical Trial Platform
Soft Tissue Sarcoma
12/23
10/25
Fillful-03, NCT05122494: A Phase Ⅲ Study of the Efficacy and Safety of Hemay022+Aromatase Inhibitor(AI) in Participants With ER+/HER2+ Advanced or Metastatic Breast Cancer

Recruiting
3
339
RoW
Hemay022+AI, Lapatinib+Capecitabine
Tianjin Hemay Oncology Pharmaceutical Co., Ltd
Breast Cancer
02/24
06/24
ACE-Breast-02, CTR20201708: Clinical study evaluating ARX788 in the treatment of HER2-positive advanced breast cancer

Recruiting
2/3
440
China
capecitabine - Generic mfg., lapatinib - Generic mfg., anvatabart opadotin (ARX788) - Ambrx
Zhejiang Pharmaceutical Co., Ltd./Zhejiang Xinma Biopharmaceutical Co., Ltd.
HER2-positive breast cancer
 
 
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
NCT00470704: Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark P2 data-SABCS
Dec 2011 - Dec 2011: P2 data-SABCS
Active, not recruiting
2
87
US
Lapatinib, Tykerb, Herceptin, trastuzumab
Nancy Lin, MD, GlaxoSmithKline, Novartis
Breast Cancer
11/13
12/24
2013-001203-36: Clinical trial to assess wether Lapatinib in association with Capecitabine and Radiation performs better than Capecitabine and Radiation in patients with localized rectal cancer Ensaio clínico para avaliar se a associação de Lapatinib com Capecitabina e Radioterapia é melhor do que Capecitabina e Radioterapia em doentes com cancro do recto localizado

Ongoing
2
80
Europe
Film-coated tablet, Tyverb
Instituto Português de Oncologia do Porto Francisco Gentil, EPE, GlaxoSmithKline, IPO Porto FG, EPE
Rectal cancer stage II Rectal cancer stage III Cancro do Reto, estádio II Cancro do Reto, estádio III, Rectal Cancer Cancro do Reto, Diseases [C] - Cancer [C04]
 
 
NCT01306045: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

Active, not recruiting
2
647
US
AZD6244, Selumetinib, MK-2206, Lapatinib, Tykerb, Erlotinib, Tarceva, Sunitinib, Sutent, Molecular Profiling
National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic
02/14
12/24
HELEX, NCT00999804: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Active, not recruiting
2
128
US
Lapatinib, TyKerb, Letrozole, Femara, Trastuzumab, Herceptin
Baylor Breast Care Center, Translational Breast Cancer Research Consortium, GlaxoSmithKline
Breast Cancer
11/14
01/24
2006-001055-35: Lapatinib Pre-Surgical Phase 2 Study in Patients with Primary Breast Cancer

Ongoing
2
150
Europe
lapatinib, GW572016, Tyverb, Tyverb
Imperial College London
Patients with primary breast cancer and new primary or recurrent breast cancer
 
 
2006-006619-64: Randomised Controlled Trial of Lapatinib (A Her1/2 Tyrosine Kinase Inhibitor) on Epithelial Proliferation and Apoptosis in Ductal Cancer in Situ.

Ongoing
2
80
Europe
Lapatinib, Tykerb, Tykerb
University Hospital of South Manchester NHS Foundation Trust, University of Manchester
Women with a core biopsy diagnosis of histologically proven Her2 positive DCIS (or DCIS and invasive cancer). Women undergoing re-excision of DCIS will be eligible provided residual DCIS is present in the re-excision specimen.
 
 
2007-007027-40: A Multicenter open-label, phase I/II dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2 positive advanced or metastatic breast cancer

Ongoing
2
24
Europe
Lapatinib, Docétaxel, Taxotère, Taxotère
Centre Georges-François Leclerc
HER 2 positive advanced or metastatic breast cancer
 
 
2007-002155-17: A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cells

 
2
31
Europe
lapatinib, GW572016, Tyverb, Tyverb
GlaxoSmithKline Research and Development Limited, GlaxoSmithKline Research & Development Limited
Advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cells
 
 
2009-014456-29: PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA

Ongoing
2
18
Europe
TYVERB, TYVERB
ISTITUTO NAZIONALE PER LA CURA TUMORI
Advanced chordoma EGFR/Her2Neu positive
 
 
2010-019982-27: Targeted therapy selection based on tumor tissue kinase activity profiles for patients with advanced solid malignancies, an exploratory study

Ongoing
2
45
Europe
sunitinib, Sutent, Nexavar, Tarceva, Afinitor, Tyverb, Sprycel, Sutent, Nexavar, Tarceva, Afinitor, Tyverb, Sprycel
VU medical center
Advanced (metastasized or inoperable) solid cancer
 
 
2010-020966-34: A study where the treatment given prior to surgery is compared to assess 2 different treatment combinations (TCH and TCHL).

Ongoing
2
80
Europe
Lapatinib, Carboplatin, Tyverb, Taxotere, Herceptin, Carboplatin, Tyverb, Taxotere, Herceptin, Carboplatin
ICORG, GSK
Her 2 positive locally advanced or primary breast cancer
 
 
2010-018389-22: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared with EC90 followed by weekly paclitaxel and trastuzumab (PX-T), as neoadjuvant therapy in patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.

 
2
35
Europe
Lapatinib, Trastuzumab, GW572016, Tyverb, Herceptin, Tyverb, Herceptin
GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A.
patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm.
 
01/11
2010-019602-16: A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers

Ongoing
2
25
Europe
Oxaliplatin, Capecitabine(Xeloda) 150 mg tablets, Capecitabine (Xeloda) 500mg tablets, Lapatinib (Tyverb), Eloxatin, Xeloda 150mg tablets, Xeloda, Tyverb, Eloxatin, Xeloda 150mg tablets, Xeloda, Tyverb
Cambridge University Hospitals NHS Foundation Trust
Oesophagogastric adenocarcinoma
 
 
2014-000256-28: A study to assess the use of Octreotide in the prevention or reduction of diarrhoea associated with lapatinib and capecitabine treatment in patients with metastatic breast cancer.

Ongoing
2
40
Europe
Sandostatin® LAR®, Sandostatin, N/A, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb
GlaxoSmithKline research & Development, GlaxoSmithKline R&D
Diarrhoea associated with treatment with lapatinib and capecitabine for metastatic breast cancer
 
 
NCT02668939: Presurgical Treatment With Single-Agent Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Six Cycles of Docetaxel & Carboplatin With Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib in Patients With HER2/+ Operable Breast Cancer

Active, not recruiting
2
140
US
TCH, Trastuzumab, Docetaxel, carboplatin, TCTy, Lapatinib, docetaxel, TCHTy, lapatinib
Translational Oncology Research International, Sanofi, GlaxoSmithKline
Adenocarcinoma of the Breast, Tumor HER2/Neu Positive
01/16
 
2008-000528-22: Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpression Studio di fase I-II con Lapatinib in combinazione con capecitabina e vinorelbina come seconda linea di trattamento in pazienti con carcinoma mammario con iperespressione di ErbB2 localmente avanzato o metastatico in progressione ad una prima linea di chemioterapia associata a trastuzumab

Ongoing
2
80
Europe
XELODA, NAVELBINE 10, XELODA, NAVELBINE 10
GRUPPO ONCOLOGICO ITALIANO DI RICERCA
Patients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breast Pazienti con carcinoma mammario metastatico o con recidiva locale HER2 positivo
 
 
NCT01612351: Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery

Active, not recruiting
2
40
US
Carboplatin, Paraplatin, Paclitaxel, Taxol, Lapatinib, Tykerb, Cisplatin, Platinol, Ipsilateral Radiation, Radiation therapy, Bilateral Radiation, Transoral Surgery, Surgery
UNC Lineberger Comprehensive Cancer Center, GlaxoSmithKline
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
11/16
11/31
NCT01273610 / 2004-002614-10: Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

Active, not recruiting
2
40
US
Lapatinib, Tykerb, Tyverb, GSK572016, GW-572016, GW2016, Trastuzumab, Herceptin, laboratory biomarker analysis, Correlative studies, pharmacological study
City of Hope Medical Center, GlaxoSmithKline, Novartis
Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services
02/18
02/25
ELTOP, UMIN000005219: Japanese A Randomized Phase II Study Comparing Trastuzumab + Capecitabine Combination (HX Therapy) Versus Lapatinib + Capecitabine Combination (LX Therapy) in HER2-Positive Metastatic or Unresectable Locally Advanced Breast Cancer Previously Treated with

Completed
2
110
Japan
Herceptin (trastuzumab) - Roche, capecitabine - Generic mfg., lapatinib - Generic mfg.
GlaxoSmithKline K.K.
HER2-positive metastatic or unresectable locally advanced breast cancer
 
 
2019-002181-12: OPTIMAL THERAPY FOR HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS TERAPIA OTTIMALE PER LE PAZIENTI AFFETTE DA TUMORE DELLA MAMMELLA MESTASTATICO HER2 POSITIVO

Not yet recruiting
2
101
Europe
KADCYLA, Capecitabina, TYVERB, [Trastuzumab emtansine], [Capecitabina], [LAPATINIB], Powder and solvent for solution for infusion, Film-coated tablet, KADCYLA, TYVERB - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 70 COMPRESSE
ISTITUTI FISIOTERAPICI OSPITALIERI, Ministero della Salute - Ricerca Finalizzata GR 2018-12367431
HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, Diseases [C] - Cancer [C04]
 
 
TRYHARD, NCT01711658: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.

Completed
2
142
Canada, US
IMRT, Cisplatin, placebo, Lapatinib
Radiation Therapy Oncology Group, GlaxoSmithKline, Novartis
Non-HPV Locally Advanced Head and Neck Cancer
12/20
09/22
ChiCTR1800015814: A multi-center phase II clinical trial of HER2 positive metastatic breast cancer treated by lapatinib trastuzumab combined with single-drug chemotherapy

Not yet recruiting
2
120
 
lapatinib+trastuzumab+Mono-chemotherapy
First People's Hospital of Foshan; First People's Hospital of Foshan, Patients at his own expense and National insurance reimbursement
breast cancer
 
 
NCT01591577: Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme

Completed
2
50
US
Lapatinib/Temozolomide/radiation
Jonsson Comprehensive Cancer Center, GlaxoSmithKline, Novartis
Newly Diagnosed Glioblastoma Multiforme
05/24
05/24
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

Recruiting
2
900
Europe
Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab
Centre Leon Berard, National Cancer Institute, France
Malignant Solid Neoplasms
01/26
10/27
NCT04831528: Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study

Not yet recruiting
2
100
NA
Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others
Fudan University
Metastatic Colorectal Cancer
06/25
06/26
2014-002209-39: Phase I/II study with lapatinib plus trametinib in patients with metastatic non-small cell lung cancer with a mutation in the KRAS gene Fase I/II studie met de combinatie van lapatinib met trametinib bij patiënten met uitgezaaid niet kleincellig longkanker met een KRAS genmutatie

Ongoing
1/2
132
Europe
Lapatinib, trametinib, docetaxel, Tablet, Film-coated tablet, Concentrate and solvent for concentrate for solution for infusion, Mekinist
The Netherlands Cancer Institute, Novartis
non-small cell lung cancer niet-kleincellig longkanker, lung cancer longkanker, Diseases [C] - Cancer [C04]
 
 
2008-001662-85: Phase 1/2 Randomized, Open-label, Three Arm Study of Neratinib (HKI-272) vs. Neratinib + Capecitabine vs. Lapatinib + Capecitabine, in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or locally advanced Breast Cancer

Ongoing
1/2
40
Europe
neratinib, HKI-272, XELODA 150 mg comprimidos recubiertos con película, TYVERB 250 mg comprimidos recubiertos con película, XELODA 150 mg comprimidos recubiertos con película, TYVERB 250 mg comprimidos recubiertos con película
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
Solid tumors (part 1) and metastatic breast cancer (part 2)
 
 
2009-009928-37: Phase 1/2 Studie:CONKO-008Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie

Ongoing
1/2
95
Europe
Lapatinib, GW572016, Tyverb, MEDOXA, Fluorouracil-GRY, Calciumfolinat-GRY, Tyverb, MEDOXA, Fluorouracil-GRY, Calciumfolinat-GRY
Charite Universitätsmedizin Berlin
Pancreatic cancer patients who failed first line therapy with gemcitabine
 
 
2011-002167-23: A phase Ib/II open-label study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2+/PI3K-activated, trastuzumab-resistant locally advanced, recurrent and metastatic breast cancer. Etude de phase Ib/II évaluant la sécurité et l’efficacité du BKM120 en combinaison avec le lapatinib dans les cancers du sein récidivants, localement avancés ou métastatiques, HER2+ résistants au trastuzumab avec activation de la voie PI3K

Ongoing
1/2
59
Europe
BKM 120, TYVERB, TYVERB
Institut Paoli-Calmettes, Programme Hospitalier de Recherche Clinique (PHRC), Laboratoires Novartis
locally advanced, recurrent and metastatic breast cancer.
 
 
2019-004987-23: RASTRIC-trial: investigating the safety and efficacy of a new three drug treatment combination for RAS-mutated metastastic colorectal cancer. RASTRIC-studie: onderzoek naar de veiligheid en effectiviteit van een nieuwe behandeling met drie middelen voor RAS-gemuteerde uitgezaaide dikke darmkanker.

Not yet recruiting
1/2
50
Europe
Mektovi, Tyverb, vinorelbine, EMEA/H/C/004579, EMEA/H/C/000795, RVG 35294, Film-coated tablet, Concentrate and solvent for solution for infusion, Mektovi, Tyverb, vinorelbine
UMC Utrecht, ONCODE institute, UMC Utrecht
colorectal cancer colorectaal carcinoom, colorectal cancer dikkedarmkanker, Diseases [C] - Cancer [C04]
 
 
NCT02101905: Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Active, not recruiting
1
29
US
Laboratory Biomarker Analysis, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Pharmacological Study, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, Gliosarcoma, Mixed Glioma, Recurrent Adult Brain Neoplasm, Recurrent Glioblastoma
10/21
10/24
NCT01947023: Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Active, not recruiting
1
21
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dabrafenib, BRAF Inhibitor GSK2118436, GSK 2118436, GSK 2118436A, GSK-2118436, GSK-2118436A, GSK2118436, GSK2118436A, Dabrafenib Mesylate, Dabrafenib Methanesulfonate, GSK2118436 Methane Sulfonate Salt, GSK2118436B, Tafinlar, Echocardiography, EC, Lapatinib, GSK572016, GW 2016, GW 572016, GW-572016, GW2016, GW572016, Lapatinib Ditosylate, Tykerb, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
12/24
12/24
NCT04608409: Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Active, not recruiting
1
15
US
Lapatinib and Paclitaxel
Frederick R. Ueland, M.D., National Cancer Institute (NCI)
Ovarian Cancer
06/25
06/25
ChiCTR1900024127: A single-center, one-arm exploratory clinical study for Apatinib mesylate combined with S-1 in the treatment of second-line or higher radiochemotherapy failure or sinister advanced small cell lung cancer

Recruiting
N/A
20
 
Apatinib Mesylate combined with Tegafur
Tianjin Medical University Cancer Institute & Hospital; Tianjin Medical University Cancer Institute & Hospital, Hengrui Pharmaceutical Co., Ltd.
SCLC
 
 
NCT02158507: Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Active, not recruiting
N/A
23
US
Combination of Veliparib + Lapatinib, Veliparib (ABT-888), Lapatinib (Tykerb)
University of Alabama at Birmingham, Breast Cancer Research Foundation of Alabama, GlaxoSmithKline, AbbVie
Metastatic Triple Negative Breast Cancer
12/24
12/24
ChiCTR2200061912: Prospective study of troponin I as a predictor of cardiotoxicity induced by lapatinib combined with doxorubicin in patients with breast cancer

Not yet recruiting
N/A
80
 
Shanghai Tenth People's Hospital; Shanghai Tenth People's Hospital, self-funded
Breast cancer
 
 
NCT04899128: Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer

Active, not recruiting
N/A
100
RoW
Pyrotinib
The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
08/20
06/21
NCT05467189: Antineoplastic Drugs in Elderly Patients

Recruiting
N/A
500
RoW
Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib (Antineoplastic drugs), Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc
Shandong University, Shandong Provincial Qianfoshan Hospital, The Second Hospital of Shandong University, The Affiliated Hospital of Qingdao University
Cancer
03/28
06/28

Download Options